Infiltrating bladder urothelial carcinoma

This trial tests whether combining two drugs—disitamab vedotin and toripalimab—with or without pelvic lymph node removal can help people with muscle-invasive bladder cancer keep their bladder. Participants, who have HER2-positive tumors and decline bladder removal surgery, will r…

Researchers are testing whether adding sacituzumab tirumotecan and subcutaneous pembrolizumab to chemoradiotherapy helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning. The trial enrolls about 400 people who have chosen bladder pres…

This phase 2 trial tests whether adding a gene therapy called nadofaragene firadenovec to standard chemotherapy and immunotherapy can improve outcomes for people with muscle invasive bladder cancer before they have their bladder removed. The gene therapy is placed directly into t…

Researchers are testing whether combining enfortumab vedotin and pembrolizumab can shrink muscle-invasive bladder cancer enough to avoid removing the bladder or using radiation. The trial enrolls 25 adults with confirmed muscle-invasive urothelial carcinoma that has not spread. P…

This phase 2 trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, given before surgery to people with muscle-invasive bladder cancer or upper tract urothelial carcinoma. The goal is to see if the drugs can shrink or eliminate the cancer enough that some b…

This study tests a personalized approach for people with muscle-invasive bladder cancer who are scheduled for bladder removal surgery. Before treatment, a small sample of the tumor is used to grow cell clusters in the lab. These clusters are tested against different drugs to find…

This study tests whether combining two drugs (trastuzumab rezetecan and camrelizumab) before surgery can improve outcomes for people with a certain type of muscle-invasive bladder cancer (HER2-positive). About 44 adults will receive the treatment to see if it helps eliminate canc…

This study tests whether giving two drugs (trastuzumab rezetecan and adebrelimab) before surgery can eliminate or shrink tumors in people with a specific type of muscle-invasive bladder cancer (HER2-positive). About 58 adults will receive the combination, then have their bladder …

This study tests whether a combination of disitamab vedotin (a targeted drug) and toripalimab (an immunotherapy) works better than standard chemotherapy plus immunotherapy for people with HER2-positive muscle-invasive bladder cancer. About 240 participants will receive treatment …

This study tests whether adding a probiotic (Clostridium butyricum) to a combination of targeted therapy (Disitamab Vedotin) and immunotherapy (Toripalimab) can help preserve the bladder in people with muscle-invasive bladder cancer who cannot take the chemotherapy drug cisplatin…

This study tests whether adding immunotherapy (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with muscle-invasive bladder cancer. About 30 participants will receive the combination therapy, and researchers will monitor how the tumor and immu…

This study compares two treatments for muscle-invasive bladder cancer: radiation combined with chemotherapy versus surgery to remove the bladder. About 336 adults with this cancer will be randomly assigned to one of the two groups. The goal is to see if the non-surgical approach …

This phase 2 trial tests a combination of two drugs (toripalimab and RC48-ADC) plus radiation in 45 people with HER2-positive muscle-invasive bladder cancer. The goal is to see if this approach can eliminate the cancer and allow patients to keep their bladder after initial chemot…

This study tests whether two drugs, Vedisertib and Toripalimab, can shrink muscle-invasive bladder cancer so patients can keep their bladder. About 59 adults with early-stage cancer will receive the drugs in cycles, with regular checks to see if the cancer disappears. If it does,…

This phase 2 trial tests a dose-dense (faster) schedule of two chemotherapy drugs, gemcitabine and cisplatin, given before surgery for muscle-invasive bladder cancer. The goal is to see if this approach can completely eliminate the tumor in the bladder and lymph nodes. Thirty eli…

This phase 2 trial tests two drugs—disitamab vedotin and toripalimab—as a way to treat HER2-positive muscle-invasive bladder cancer without removing the bladder. About 60 adults with locally advanced cancer will receive different cycles of the combination. The main goal is to see…

This study tests a newer, more precise radiation method (adaptive radiotherapy) for people with muscle-invasive bladder cancer who cannot have surgery or choose not to. The goal is to see if this technique reduces bowel side effects like diarrhea compared to standard radiation. A…

This study looks at the well-being and medical care of people in Korea who had their bladder removed (radical cystectomy) for bladder cancer. Using nationwide insurance records, researchers will track complications, hospital stays, readmissions, and survival up to three years aft…

This registry study follows bladder cancer patients who, after receiving systemic therapy, choose not to undergo bladder removal (cystectomy) or radiotherapy. The goal is to collect data on their outcomes, such as metastasis-free survival, to better understand which patients migh…

This study examines two microscopic details in bladder cancer tumors—how deep early cancer cells have invaded and whether small clusters of cells are present at the tumor's edge. Researchers will look at tissue samples from 100 patients to see if these features can predict if the…

This study examines stored tumor samples from 100 bladder cancer patients who had their bladder removed. Researchers will measure the amount of supportive tissue, immune cells, and immune clusters near the tumor. The goal is to see if these features are linked to how long patient…

This study reviews medical records of 87 adults with muscle-invasive bladder cancer who received platinum-based chemotherapy before surgery. Researchers want to see what factors influence how well the chemo works and whether it helps patients live longer without cancer. The goal …